Therefore, the antagonistic drug targeting TNIIIA2-related active site in TN-C molecule, such as anti-TNIIIA2 antibody, might become a new therapeutic drug candidate for diseases relating hyperstimulated cell growth, such as in tumor progression. Here, TNC is linked to neoplasm.